BRAF Antikörper (N-Term)

Produktnummer ABIN7860825

Der Maus Monoklonal anti-BRAF Antikörper wird verwendet zum Nachweis von BRAF in Proben von Human. Er wurde validiert für WB und ELISA.

Kurzübersicht für BRAF Antikörper (N-Term) (ABIN7860825)

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser BRAF Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA

Klon: V600E-1321

Produktdetails anti-BRAF Antikörper

Bindungsspezifität: AA 596-606, N-Term

Verwendungszweck: BRAF (V600E Mutant Specific) (Prognostic Marker) Antibody

Spezifität: TheÇ 79oΩBRAFÇ 79oΩgene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. TheÇ 79oΩBRAFÇ 79oΩV600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8 % of all solid tumours, including 45 % of papillary thyroid carcinomas, 40-60 % of melanomas, 5-15 % of colorectal adenocarcinomas, 35 % of serous low grade and borderline ovarian carcinomas, 1-3 % of non-small cell lung cancers, and 5-7 % of cholangiocarcinomas.Ç 79oΩFurthermore, the BRAF V600E mutation is found in 100 % of hairy cell leukaemia,Ç 79oΩ54 % Erdheim-Chester disease, 38 % of Langerhans cell histocytosesÇ 79oΩand 60 % of pleomorphic xanthoastrocytomas.Ç 79oΩ

Aufreinigung: 200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G.

Immunogen: An eleven amino acid residue long synthetic peptide (aa596-606), corresponding to Cys-GLAT(E)KSRWSG from human BRAF protein. It was conjugated to KLH at the N-terminus.

Isotyp: IgG1, kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.0 mg/mL

Buffer: Prepared in 10  mM PBS

Konservierungsmittel: Azide free

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Haltbarkeit: 24 months

Details zu BRAF

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Andere Bezeichnung: BRAF

Hintergrund:

FLJ95109, 94 kDa B raf protein, B Raf proto oncogene, serine/threonine kinase, B RAF1, B-Raf proto-oncogene serine/threonine-protein kinase (p94), BRAF 1, BRAF, BRAF1, cRmil, MGC126806, MGC138284, Murine sarcoma viral (v-raf) oncogene homolog B1, NS7, oncogene BRAF1, p94, Proto-oncogene B-Raf, Proto-oncogene c-Rmil, RAFB1, RMIL, Serine/threonine-protein kinase B-raf, v-Raf murine sarcoma viral oncogene homolog B1

A431|Jurkat and HeLa cells. Human melanoma and colon carcinoma, Human Skeletal Muscles

Molekulargewicht: 35kDa (predicted)

Gen-ID: 673, 550061

UniProt: P15056

Pathways: MAPK Signalweg, RTK Signalweg, Neurotrophin Signalübertragung, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagie